Shield Therapeutics plc

Cavendish is pleased to have assisted Shield Therapeutics plc in securing its substantial $27 million funding package. This funding will allow Shield to further drive the growth of Accrufer®, the sole FDA-approved therapy for iron deficiency.

Geoff Nash, Corporate Finance Director at Cavendish, emphasises the significance of this funding, commenting:

“This funding will not only bolster the expansion of Accrufer® but also facilitate the repayment of an existing loan with AOP whilst providing Shield with the capital it needs to drive the business. Additionally, it positions the company for further investments aimed at optimising the net sales price.”

The funding structure comprises a $20 million debt facility along with up to $7 million in equity, fully utilising existing share authorities.

This capital allows Shield to maximise potential future growth and we look forward to witnessing the positive impact it will have on the business as they continue to focus on the substantial US market opportunity.